ATE442367T1 - Pyrazolo(3,4-b)pyridinverbindungen und ihre verwendung als phosphodiesterasinhibitoren - Google Patents

Pyrazolo(3,4-b)pyridinverbindungen und ihre verwendung als phosphodiesterasinhibitoren

Info

Publication number
ATE442367T1
ATE442367T1 AT03778283T AT03778283T ATE442367T1 AT E442367 T1 ATE442367 T1 AT E442367T1 AT 03778283 T AT03778283 T AT 03778283T AT 03778283 T AT03778283 T AT 03778283T AT E442367 T1 ATE442367 T1 AT E442367T1
Authority
AT
Austria
Prior art keywords
sub
sup
optionally substituted
formula
inhibitors
Prior art date
Application number
AT03778283T
Other languages
English (en)
Inventor
David Allen
Diane Coe
Caroline Cook
Michael Dowle
Christopher Edlin
Julie Hamblin
Martin Johnson
Paul Jones
Richard Knowles
Mika Lindvall
Charlotte Mitchell
Alison Redgrave
Peter Ward
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0221455A external-priority patent/GB0221455D0/en
Priority claimed from GBGB0230045.7A external-priority patent/GB0230045D0/en
Priority claimed from GB0306595A external-priority patent/GB0306595D0/en
Priority claimed from GB0308017A external-priority patent/GB0308017D0/en
Priority claimed from GB0319708A external-priority patent/GB0319708D0/en
Priority claimed from GB0321074A external-priority patent/GB0321074D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Application granted granted Critical
Publication of ATE442367T1 publication Critical patent/ATE442367T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT03778283T 2002-09-16 2003-09-12 Pyrazolo(3,4-b)pyridinverbindungen und ihre verwendung als phosphodiesterasinhibitoren ATE442367T1 (de)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GB0221455A GB0221455D0 (en) 2002-09-16 2002-09-16 Compounds
GBGB0230045.7A GB0230045D0 (en) 2002-12-23 2002-12-23 Compounds
GB0306595A GB0306595D0 (en) 2003-03-21 2003-03-21 Compounds
GB0308017A GB0308017D0 (en) 2003-04-07 2003-04-07 Compounds
GB0319708A GB0319708D0 (en) 2003-08-21 2003-08-21 Compounds
GB0321074A GB0321074D0 (en) 2003-09-09 2003-09-09 Compounds
PCT/EP2003/011814 WO2004024728A2 (en) 2002-09-16 2003-09-12 Pyrazolo[3,4-b]pyridine compounds, and their use as phosphodiesterase inhibitors

Publications (1)

Publication Number Publication Date
ATE442367T1 true ATE442367T1 (de) 2009-09-15

Family

ID=31999797

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03778283T ATE442367T1 (de) 2002-09-16 2003-09-12 Pyrazolo(3,4-b)pyridinverbindungen und ihre verwendung als phosphodiesterasinhibitoren

Country Status (23)

Country Link
US (2) US20060089375A1 (de)
EP (1) EP1539753B1 (de)
JP (1) JP2006503108A (de)
KR (1) KR20050052501A (de)
CN (1) CN100387598C (de)
AT (1) ATE442367T1 (de)
AU (1) AU2010201417A1 (de)
BR (1) BR0314392A (de)
CA (1) CA2497550A1 (de)
CY (1) CY1109619T1 (de)
DE (1) DE60329193D1 (de)
DK (1) DK1539753T3 (de)
ES (1) ES2331119T3 (de)
IL (1) IL166898A (de)
IS (1) IS7709A (de)
MA (1) MA27475A1 (de)
MX (1) MXPA05002887A (de)
NO (1) NO20050841L (de)
NZ (1) NZ538515A (de)
PL (1) PL375993A1 (de)
PT (1) PT1539753E (de)
SI (1) SI1539753T1 (de)
WO (1) WO2004024728A2 (de)

Families Citing this family (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA05002887A (es) * 2002-09-16 2005-05-27 Glaxo Group Ltd Compuestos de pirazolo[3,4-b]piridina, y su uso como inhibidores de fosfodiesterasa.
GB0230045D0 (en) * 2002-12-23 2003-01-29 Glaxo Group Ltd Compounds
EP1608652A1 (de) * 2003-03-31 2005-12-28 Vernalis (Cambridge) Limited Pyrazolopyrimidinverbindungen und deren verwendung in der medizin
CN1809351A (zh) * 2003-04-24 2006-07-26 麦克公司 Akt活性抑制剂
GB0316290D0 (en) 2003-07-11 2003-08-13 Glaxo Group Ltd Novel compounds
WO2005058892A1 (en) * 2003-12-19 2005-06-30 Glaxo Group Limited Pyrazolo [3,4-b] pyridine compounds, and their use as phosphodiesterase inhibitors
GB0405933D0 (en) * 2004-03-16 2004-04-21 Glaxo Group Ltd Compounds
AU2005223351A1 (en) 2004-03-16 2005-09-29 Glaxo Group Limited Pyrazolo[3,4-b]pyridine compound, and its use as a PDE4 inhibitor
US7846973B2 (en) 2004-04-02 2010-12-07 Theravance, Inc. Chemical process and new crystalline form
AR049384A1 (es) 2004-05-24 2006-07-26 Glaxo Group Ltd Derivados de purina
TWI307630B (en) 2004-07-01 2009-03-21 Glaxo Group Ltd Immunoglobulins
ES2319797T3 (es) * 2004-07-05 2009-05-12 Astellas Pharma Inc. Derivados de pirazolopiridina.
GB0418045D0 (en) 2004-08-12 2004-09-15 Glaxo Group Ltd Compounds
EP1841780B1 (de) 2005-01-10 2011-07-27 Glaxo Group Limited Androstan-17-alpha-carbonat-derivate zur verwendung bei der behandlung allergischer und entzündlicher zustände
GB0514809D0 (en) 2005-07-19 2005-08-24 Glaxo Group Ltd Compounds
JP5323484B2 (ja) * 2005-09-29 2013-10-23 グラクソ グループ リミテッド ピラゾロ［３，４−ｂ］ピリジン化合物及びそのＰＤＥ４阻害薬としての使用
TW200730498A (en) 2005-12-20 2007-08-16 Glaxo Group Ltd Compounds
US8927546B2 (en) 2006-02-28 2015-01-06 Dart Neuroscience (Cayman) Ltd. Therapeutic piperazines
US7829713B2 (en) * 2006-02-28 2010-11-09 Helicon Therapeutics, Inc. Therapeutic piperazines
CA2645137A1 (en) * 2006-03-07 2007-09-13 James F. Blake Heterobicyclic pyrazole compounds and methods of use
KR20090003349A (ko) 2006-04-20 2009-01-09 글락소 그룹 리미티드 화합물
GB0611587D0 (en) 2006-06-12 2006-07-19 Glaxo Group Ltd Novel compounds
AR061571A1 (es) 2006-06-23 2008-09-03 Smithkline Beecham Corp Compuesto sal del acido toluenosulfonico de 4-{[6-cloro-3-({[(2- cloro-3-fluorofenil) amino]carbonil} amino)- 2- hidroxifenil]sulfonil] -1- piperazinacarbxilato de 1.1-dimetiletilo, composicion farmaceutica que lo comprende su uso para la fabricacion de un medicamento combinacion farmaceutica con un
CA2659539A1 (en) 2006-08-01 2008-02-07 Glaxo Group Limited Pyrazolo[3,4-b]pyridine compounds, and their use as pde4 inhibitors
PE20081889A1 (es) 2007-03-23 2009-03-05 Smithkline Beecham Corp Indol carboxamidas como inhibidores de ikk2
WO2009041591A1 (ja) * 2007-09-28 2009-04-02 Kyowa Hakko Kirin Co., Ltd. 縮環ピリジン誘導体
EP2070929A1 (de) * 2007-12-11 2009-06-17 Bayer Schering Pharma Aktiengesellschaft Alkynylarylverbindungen und Salze davon, pharmazeutische Zusammensetzungen damit sowie Verfahren zu ihrer Herstellung und Verwendung
PE20091553A1 (es) 2008-02-06 2009-10-30 Glaxo Group Ltd Farmacoforos duales - antagonistas muscarinicos de pde4
AR070562A1 (es) 2008-02-06 2010-04-21 Glaxo Group Ltd Farmacoforos duales - antagonistas muscarinicos de pde4
PE20091563A1 (es) * 2008-02-06 2009-11-05 Glaxo Group Ltd Farmacoforos duales - antagonistas muscarinicos de pde4
BRPI0912267A2 (pt) 2008-05-23 2015-10-13 Amira Pharmaceuticals Inc sal farmaceuticamente aceitável, composição farmacêutica, artigo de fabricação, métodos para tratar asma, rinite alérgica, doença, lesões gástricas e dor, métodos para prevenir broncoconstrição e rinite alérgica, uso de um sal farmaceuticamente aceitável, e, processo para a preparação de um sal farmaceuticamente aceitável.
ES2566339T3 (es) 2008-06-05 2016-04-12 Glaxo Group Limited Derivados de 4-carboxamida indazol útiles como inhibidores de PI3-quinasas
WO2010094643A1 (en) 2009-02-17 2010-08-26 Glaxo Group Limited Quinoline derivatives and their uses for rhinitis and urticaria
US8524751B2 (en) 2009-03-09 2013-09-03 GlaxoSmithKline Intellecutual Property Development 4-oxadiazol-2-YL-indazoles as inhibitors of P13 kinases
JP2012520257A (ja) 2009-03-10 2012-09-06 グラクソ グループ リミテッド Ｉｋｋ２阻害剤としてのインドール誘導体
EP2408769A1 (de) 2009-03-17 2012-01-25 Glaxo Group Limited Als itk-inhibitoren verwendete pyrimidinderivate
WO2010107958A1 (en) 2009-03-19 2010-09-23 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 6 (STAT6) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
JP2012520685A (ja) 2009-03-19 2012-09-10 メルク・シャープ・エンド・ドーム・コーポレイション 低分子干渉核酸（ｓｉＮＡ）を用いたＧＡＴＡ結合タンパク質３（ＧＡＴＡ３）遺伝子発現のＲＮＡ干渉媒介性阻害
EP2408916A2 (de) 2009-03-19 2012-01-25 Merck Sharp&Dohme Corp. Rna-interferenz-vermittelte hemmung der genexpression von ctgf (connective tissue growth factor) unter verwendung von sina (short interfering nucleic acid)
EA201171144A1 (ru) 2009-03-19 2012-04-30 Мерк Шарп Энд Домэ Корп. ОПОСРЕДОВАННОЕ РНК-ИНТЕРФЕРЕНЦИЕЙ ИНГИБИРОВАНИЕ ЭКСПРЕССИИ ГЕНА ГОМОЛОГА 1 BTB И CNC, ОСНОВНОГО ФАКТОРА ТРАНСКРИПЦИИ С ЛЕЙЦИНОВОЙ МОЛНИЕЙ 1 (Bach1) С ИСПОЛЬЗОВАНИЕМ МАЛОЙ ИНТЕРФЕРИРУЮЩЕЙ НУКЛЕИНОВОЙ КИСЛОТЫ (миНК)
WO2010111468A2 (en) 2009-03-27 2010-09-30 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF THE NERVE GROWTH FACTOR BETA CHAIN (NGFß) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (SINA)
US20120022142A1 (en) 2009-03-27 2012-01-26 Merck Sharp & Dohme Corp. RNA Interference Mediated Inhibition of Signal Transducer and Activator of Transcription 1 (STAT1) Gene Expression Using Short Interfering Nucleic Acid (siNA)
US20120022143A1 (en) 2009-03-27 2012-01-26 Merck Sharp & Dohme Corp RNA Interference Mediated Inhibition of the Thymic Stromal Lymphopoietin (TSLP) Gene Expression Using Short Interfering Nucliec Acid (siNA)
JP2012521760A (ja) 2009-03-27 2012-09-20 メルク・シャープ・エンド・ドーム・コーポレイション 低分子干渉核酸（ｓｉＮＡ）を用いたアポトーシスシグナル調節キナーゼ１（ＡＳＫ１）遺伝子発現のＲＮＡ干渉媒介性阻害
KR20110138223A (ko) 2009-03-27 2011-12-26 머크 샤프 앤드 돔 코포레이션 짧은 간섭 핵산 (ｓｉＮＡ)을 사용한 세포간 부착 분자 1 (ＩＣＡＭ-1) 유전자 발현의 ＲＮＡ 간섭 매개 억제
EP2421834A1 (de) 2009-04-24 2012-02-29 Glaxo Group Limited Pyrazol- und triazolcarbonsäureamide als inhibitoren des crac-kanals
US20100273744A1 (en) 2009-04-24 2010-10-28 Paul Martin Gore Compounds
CN102459253B (zh) 2009-04-30 2015-03-25 葛兰素集团有限公司 作为pi3-激酶抑制剂的*唑取代的吲唑化合物
WO2011067366A1 (en) 2009-12-03 2011-06-09 Glaxo Group Limited Indazole derivatives as pi 3 - kinase inhibitors
EP2507223A1 (de) 2009-12-03 2012-10-10 Glaxo Group Limited Benzpyrazolderivate als p13-kinasehemmer
US20120238559A1 (en) 2009-12-03 2012-09-20 Glaxo Group Limited Novel compounds
US20120272951A1 (en) 2009-12-16 2012-11-01 3M Innovative Properties Company Formulations and methods for controlling mdi particle size delivery
WO2011110575A1 (en) 2010-03-11 2011-09-15 Glaxo Group Limited Derivatives of 2-[2-(benzo- or pyrido-) thiazolylamino]-6-aminopyridine, useful in the treatment of respiratoric, allergic or inflammatory diseases
GB201007203D0 (en) 2010-04-29 2010-06-16 Glaxo Group Ltd Novel compounds
UY33373A (es) * 2010-05-10 2011-12-30 Gilead Sciences Inc ?Compuestos de pirazolopiridina bifuncionales, su uso en terapia y composiciones que los comprenden?.
EP2397482A1 (de) 2010-06-15 2011-12-21 Almirall, S.A. Heteroarylimidazolon-Derivate als JAK-Inhibitoren
WO2012007836A1 (en) 2010-07-16 2012-01-19 Purdue Pharma .Lp. Pyridine compounds as sodium channel blockers
JP5965402B2 (ja) 2010-09-08 2016-08-03 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ Ｎ−［５−［４−（５−｛［（２ｒ，６ｓ）−２，６−ジメチル−４−モルホリニル］メチル｝−１，３−オキサゾール−２−イル）−１ｈ−インダゾール−６−イル］−２−（メチルオキシ）−３−ピリジニル］メタンスルホンアミドの多形体および塩
WO2012032065A1 (en) 2010-09-08 2012-03-15 Glaxo Group Limited Indazole derivatives for use in the treatment of influenza virus infection
WO2012035055A1 (en) 2010-09-17 2012-03-22 Glaxo Group Limited Novel compounds
EP2630127A1 (de) 2010-10-21 2013-08-28 Glaxo Group Limited Pyrazolverbindungen, gegen allergie-, entzündungs- und immunerkrankungen
EP2630126B1 (de) 2010-10-21 2015-01-07 Glaxo Group Limited Pyrazolverbindungen gegen allergie-, immun- und entzündungserkrankungen
GB201018124D0 (en) 2010-10-27 2010-12-08 Glaxo Group Ltd Polymorphs and salts
US9358233B2 (en) 2010-11-29 2016-06-07 Boehringer Ingelheim International Gmbh Method for treating acute myeloid leukemia
CN102485724B (zh) * 2010-12-06 2015-08-12 中国人民解放军军事医学科学院毒物药物研究所 取代噻吩基吡唑并吡啶类化合物及其医药用途
US20140005188A1 (en) 2011-03-11 2014-01-02 Glaxo Group Limited Pyrido[3,4-b]pyrazine derivatives as syk inhibitors
GB201104153D0 (en) 2011-03-11 2011-04-27 Glaxo Group Ltd Novel compounds
US9370535B2 (en) 2011-05-17 2016-06-21 Boehringer Ingelheim International Gmbh Method for treatment of advanced solid tumors
EP2527344A1 (de) 2011-05-25 2012-11-28 Almirall, S.A. Als Medikamente zur Behandlung von myeloproliferativen Krankheiten, Transplantatabstossung, immunbedingten und entzündlichen Erkrankungen geeignete Pyridin-2(1H-)-on-Derivate
US9206127B2 (en) 2012-03-16 2015-12-08 Purdue Pharm, L.P. Substituted pyridines as sodium channel blockers
US9714252B2 (en) 2012-12-20 2017-07-25 Purdue Pharma L.P. Cyclic sulfonamides as sodium channel blockers
WO2015011236A1 (en) 2013-07-26 2015-01-29 Boehringer Ingelheim International Gmbh Treatment of myelodysplastic syndrome
WO2015055691A1 (en) 2013-10-17 2015-04-23 Glaxosmithkline Intellectual Property Development Limited Pi3k inhibitor for treatment of respiratory disease
EP3057587A1 (de) 2013-10-17 2016-08-24 GlaxoSmithKline Intellectual Property Development Limited Pi3k-hemmers zur behandlung von atemwegserkrankungen
ES2871027T3 (es) 2014-03-27 2021-10-28 Eicosis Llc Inhibidores potentes de la epóxido hidrolasa soluble
US10730866B2 (en) 2014-04-07 2020-08-04 Purdue Pharma L.P. Indole derivatives and use thereof
TW201625247A (zh) 2014-05-12 2016-07-16 葛蘭素史密斯克藍智慧財產權有限公司 用於治療傳染性疾病之醫藥組合物
US9867831B2 (en) 2014-10-01 2018-01-16 Boehringer Ingelheim International Gmbh Combination treatment of acute myeloid leukemia and myelodysplastic syndrome
CN107531707B (zh) 2015-05-12 2020-01-10 大鹏药品工业株式会社 氮杂二环式化合物的结晶
EP3156405A1 (de) 2015-10-13 2017-04-19 Boehringer Ingelheim International GmbH Spirocyclische etherderivate von pyrazolo[1,5-a]pyrimidin-3-carboxamid
GB201602527D0 (en) 2016-02-12 2016-03-30 Glaxosmithkline Ip Dev Ltd Chemical compounds
JP2019524792A (ja) 2016-08-08 2019-09-05 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ 化合物
CN107964011A (zh) * 2016-10-19 2018-04-27 中国人民解放军军事医学科学院毒物药物研究所 取代吡唑并吡啶类衍生物及其医药用途
KR102590848B1 (ko) 2016-12-28 2023-10-19 다트 뉴로사이언스, 엘엘씨 Pde2 억제제로서 치환된 피라졸로피리미디논 화합물
GB201706102D0 (en) 2017-04-18 2017-05-31 Glaxosmithkline Ip Dev Ltd Chemical compounds
GB201712081D0 (en) 2017-07-27 2017-09-13 Glaxosmithkline Ip Dev Ltd Chemical compounds
MY202326A (en) 2017-09-14 2024-04-24 Daiichi Sankyo Co Ltd Compound having cyclic structure
EP3704102B1 (de) 2017-10-30 2024-02-28 The United States of America, as represented by the Secretary, Department of Health and Human Services Substituierte chinolinanaloga als aldehyd-dehydrogenase-1a1(aldh1a1)-inhibitoren
JP7254078B2 (ja) 2017-11-27 2023-04-07 ダート・ニューロサイエンス・エルエルシー Ｐｄｅ１阻害剤としての置換フラノピリミジン化合物
CN111875594A (zh) * 2020-07-21 2020-11-03 中国药科大学 具有磷酸二酯酶4b抑制活性的吲唑杂环类化合物
US20230364100A1 (en) * 2020-09-10 2023-11-16 Vanda Pharmaceuticals, Inc. Methods of treating pde iv-mediated diseases or conditions
WO2025072040A1 (en) * 2023-09-28 2025-04-03 Merck Sharp & Dohme Llc Azaindazole derivatives useful as hcn2 modulators

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US598838A (en) * 1898-02-08 William b
US598973A (en) * 1898-02-15 Water-heater and smoke-consumer
US3925388A (en) * 1971-08-05 1975-12-09 Squibb & Sons Inc 4-Piperazino-{8 3,4-b{9 pyridine-5-carboxylic acids and esters
US3833594A (en) * 1971-08-05 1974-09-03 Squibb & Sons Inc Amino derivatives of pyrazolopyridine carboxylic acids and esters
US3856799A (en) * 1971-08-05 1974-12-24 Squibb & Sons Inc Intermediates for production of amino derivatives of pyrazolopyridine carboxylic acids and esters
BE787249A (fr) * 1971-08-05 1973-02-05 Squibb & Sons Inc Derives amino d'acides pyrazolopyridine carboxyliques, leurs esters et les sels de ces composes, ainsi que leurs procedes de preparation
US4012373A (en) * 1972-09-22 1977-03-15 E. R. Squibb & Sons, Inc. Pyrazolo[3',4'-2,3]pyrido[4,5-e]b-benzo-1,5-diazepinones
US3840546A (en) * 1972-11-15 1974-10-08 Squibb & Sons Inc Amino derivatives of pyrazolopyridine carboxamides
US3979399A (en) * 1972-11-15 1976-09-07 E. R. Squibb & Sons, Inc. Amino derivatives of pyrazolopyridine carboxamides
US3833598A (en) * 1972-12-29 1974-09-03 Squibb & Sons Inc Amino derivatives of pyrazolopyridine-6-carboxylic acids and esters
US4115394A (en) * 1974-05-06 1978-09-19 E. R. Squibb & Sons, Inc. Amino derivatives of 6-phenylpyrazolo[3,4-b]pyridines
US5593997A (en) * 1995-05-23 1997-01-14 Pfizer Inc. 4-aminopyrazolo(3-,4-D)pyrimidine and 4-aminopyrazolo-(3,4-D)pyridine tyrosine kinase inhibitors
US6326379B1 (en) * 1998-09-16 2001-12-04 Bristol-Myers Squibb Co. Fused pyridine inhibitors of cGMP phosphodiesterase
JP2002020386A (ja) * 2000-07-07 2002-01-23 Ono Pharmaceut Co Ltd ピラゾロピリジン誘導体
US20050043319A1 (en) * 2001-08-14 2005-02-24 Exonhit Therapeutics Sa Molecular target of neurotoxicity
GB0230045D0 (en) * 2002-12-23 2003-01-29 Glaxo Group Ltd Compounds
MXPA05002887A (es) * 2002-09-16 2005-05-27 Glaxo Group Ltd Compuestos de pirazolo[3,4-b]piridina, y su uso como inhibidores de fosfodiesterasa.
WO2005058892A1 (en) * 2003-12-19 2005-06-30 Glaxo Group Limited Pyrazolo [3,4-b] pyridine compounds, and their use as phosphodiesterase inhibitors

Also Published As

Publication number Publication date
DE60329193D1 (de) 2009-10-22
AU2010201417A1 (en) 2010-04-29
DK1539753T3 (da) 2010-01-04
US20060089375A1 (en) 2006-04-27
US20080175914A1 (en) 2008-07-24
JP2006503108A (ja) 2006-01-26
BR0314392A (pt) 2005-07-12
EP1539753A2 (de) 2005-06-15
CN100387598C (zh) 2008-05-14
CA2497550A1 (en) 2004-03-25
PT1539753E (pt) 2009-12-10
NO20050841L (no) 2005-06-15
KR20050052501A (ko) 2005-06-02
MXPA05002887A (es) 2005-05-27
MA27475A1 (fr) 2005-08-01
ES2331119T3 (es) 2009-12-22
NZ538515A (en) 2007-04-27
EP1539753B1 (de) 2009-09-09
CN1694882A (zh) 2005-11-09
IL166898A (en) 2010-06-30
AU2003285300A1 (en) 2004-04-30
CY1109619T1 (el) 2014-08-13
IS7709A (is) 2005-02-24
WO2004024728A3 (en) 2004-10-21
WO2004024728A2 (en) 2004-03-25
PL375993A1 (en) 2005-12-12
SI1539753T1 (sl) 2009-12-31

Similar Documents

Publication Publication Date Title
ATE442367T1 (de) Pyrazolo(3,4-b)pyridinverbindungen und ihre verwendung als phosphodiesterasinhibitoren
TW200500364A (en) Pyrazolo[3,4-b]pyridine compounds, and their use as phosphodiesterase inhibitors
NO20063340L (no) Pyrazol-[3,4-B]-pyridinforbindelser, og deres anvendelse som fosfodiesteraseinhibitorer
GEP20104973B (en) Triazolopyridinylsulfanyl derivatives as p38 map kinase inhibitors
NO20084997L (no) Pyrazolo[3,4-D]pyrimidinderivater nyttige for a behandle andedrettssykdommer
SG179437A1 (en) Pyrimidine hydrazide compounds as pgds inhibitors
DE60125026D1 (de) Fluorisochinolinderivate, verfahren zu ihrer herstellung und ihre anwendung
ATE370138T1 (de) Neue imidazopyridine und ihre verwendung
CA2564201A1 (en) Tetrahydronaphthyridine derivatives useful as histamine h3 receptor ligands
JP2013530179A (ja) 呼吸器合胞体ウイルス（ｒｓｖ）感染の処置に使用するためのウレイド−ピラゾール誘導体
RU2008112691A (ru) Азотсодержащее гетероциклическое соединение и его фармацевтическое применение
ATE504586T1 (de) Pyrazoloä3,4-büpyridinverbindungen und ihre verwendung als pde4-inhibitoren
WO2007039781A3 (en) 1,2,4-oxadioi.e derivatives with activity at the metabotropic clutamate receptors
ID27509A (id) Turunan piridin tersubstitusi-2,3 proses pembuatannya, komposisi farmasi yang mengandung senyawa tersebut, dan senyawa-antaranya
WO2006011024A3 (en) New tricyclic compounds useful for the treatment of inflammatory and allergic disorders: process for their preparation and pharmaceutical compositions containing them
RU2012131280A (ru) [4-(5-аминометил-2-фторфенил)пиперидин-1-ил]-(1н-пирролопиридинил)метаноны и их синтез
RU2011134382A (ru) Пиримидопиридазиновые производные, пригодные в качестве р38 марк
DE60203106D1 (de) Azolylcarbynol-derivative von aryl (oder heteroaryl) zur behandlung von atemwegserkrankungen
MY135776A (en) PYRAZOLO [3,4-b] PYRIDINE COMPOUNDS, AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS
NO20082051L (no) Arylsubstituert, nitrogeninneholdende, heterofyklisk forbindelse
CN106065018B (zh) 取代的吲哚化合物及其使用方法和用途

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1539753

Country of ref document: EP